MOTS vs. NMRD, AFIB, IONM, BJDX, UTRS, OSAP, NYXH, STVN, AVGR, and INVO
Should you be buying Motus GI stock or one of its competitors? The main competitors of Motus GI include Nemaura Medical (NMRD), Acutus Medical (AFIB), Assure (IONM), Bluejay Diagnostics (BJDX), Minerva Surgical (UTRS), ProSomnus (OSAP), Nyxoah (NYXH), Stevanato Group (STVN), Avinger (AVGR), and INVO Bioscience (INVO). These companies are all part of the "surgical & medical instruments" industry.
Nemaura Medical (NASDAQ:NMRD) and Motus GI (NASDAQ:MOTS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, community ranking, risk, analyst recommendations and media sentiment.
4.4% of Nemaura Medical shares are owned by institutional investors. Comparatively, 20.1% of Motus GI shares are owned by institutional investors. 40.4% of Nemaura Medical shares are owned by insiders. Comparatively, 0.3% of Motus GI shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Motus GI received 159 more outperform votes than Nemaura Medical when rated by MarketBeat users. Likewise, 65.73% of users gave Motus GI an outperform vote while only 57.14% of users gave Nemaura Medical an outperform vote.
Motus GI has higher revenue and earnings than Nemaura Medical. Nemaura Medical is trading at a lower price-to-earnings ratio than Motus GI, indicating that it is currently the more affordable of the two stocks.
Nemaura Medical has a net margin of 0.00% compared to Nemaura Medical's net margin of -3,239.75%. Motus GI's return on equity of 0.00% beat Nemaura Medical's return on equity.
In the previous week, Motus GI's average media sentiment score of 0.00 equaled Nemaura Medical'saverage media sentiment score.
Nemaura Medical currently has a consensus target price of $2.50, indicating a potential upside of 7,688.16%. Motus GI has a consensus target price of $28.88, indicating a potential upside of 42,997.01%. Given Nemaura Medical's higher possible upside, analysts plainly believe Motus GI is more favorable than Nemaura Medical.
Nemaura Medical has a beta of -0.03, indicating that its stock price is 103% less volatile than the S&P 500. Comparatively, Motus GI has a beta of 1.81, indicating that its stock price is 81% more volatile than the S&P 500.
Summary
Motus GI beats Nemaura Medical on 9 of the 14 factors compared between the two stocks.
Get Motus GI News Delivered to You Automatically
Sign up to receive the latest news and ratings for MOTS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MOTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Motus GI Competitors List
Related Companies and Tools
